HCM vs. VTRS, UTHR, RDY, SRPT, CTLT, ROIV, ELAN, ASND, LEGN, and CERE
Should you be buying HUTCHMED stock or one of its competitors? The main competitors of HUTCHMED include Viatris (VTRS), United Therapeutics (UTHR), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), Catalent (CTLT), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), and Cerevel Therapeutics (CERE). These companies are all part of the "pharmaceutical preparations" industry.
HUTCHMED (NASDAQ:HCM) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, community ranking, dividends, profitability and analyst recommendations.
HUTCHMED has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Viatris has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500.
8.8% of HUTCHMED shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 3.6% of HUTCHMED shares are held by insiders. Comparatively, 0.3% of Viatris shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
HUTCHMED received 292 more outperform votes than Viatris when rated by MarketBeat users. Likewise, 66.60% of users gave HUTCHMED an outperform vote while only 35.59% of users gave Viatris an outperform vote.
HUTCHMED has a net margin of 0.00% compared to Viatris' net margin of -0.37%. Viatris' return on equity of 16.63% beat HUTCHMED's return on equity.
In the previous week, Viatris had 2 more articles in the media than HUTCHMED. MarketBeat recorded 5 mentions for Viatris and 3 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.87 beat Viatris' score of -0.07 indicating that HUTCHMED is being referred to more favorably in the media.
HUTCHMED presently has a consensus target price of $29.70, suggesting a potential upside of 60.28%. Viatris has a consensus target price of $11.00, suggesting a potential upside of 3.77%. Given HUTCHMED's stronger consensus rating and higher possible upside, research analysts clearly believe HUTCHMED is more favorable than Viatris.
HUTCHMED has higher earnings, but lower revenue than Viatris.
Summary
HUTCHMED beats Viatris on 10 of the 16 factors compared between the two stocks.
Get HUTCHMED News Delivered to You Automatically
Sign up to receive the latest news and ratings for HCM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HUTCHMED Competitors List
Related Companies and Tools
